In a groundbreaking decision, the FDA has given the green light to two new drugs for treating sickle cell disease in patients aged 12 and above. Among them is Vertex’s Casgevy, a significant milestone as it marks the first approved application of the CRISPR genome editing technology in the United States. Bluebird Bio’s Lyfgenia, another approved drug, is a cell-based gene therapy utilizing a distinct gene modification technique to deliver modified stem cells to patients.
Read: The first CRISPR-based gene editing drug has been approved
In this week’s Tech Tuesday segment on Smile 90.4FM we discuss the first CRISPR-based gene editing drug being approved and what this means.
Listen down below.
